Dr. Madiha Iqbal, MBBS
What this data tells you about Dr. Iqbal
Dr. Madiha Iqbal is a hematology & oncology in Jacksonville, FL, with 11 years in practice. Based on federal Medicare data, Dr. Iqbal performed 56,204 Medicare services across 2,151 unique beneficiaries.
Between the years covered by Open Payments, Dr. Iqbal received a total of $12,910 from 21 pharmaceutical and/or device companies across 61 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Iqbal is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 8,000 | $38 | $180 |
| Anti-nausea injection (fosaprepitant) | 6,750 | $0 | $1 |
| Nivolumab injection (Opdivo) | 6,540 | $24 | $114 |
| Iron infusion (Feraheme) | 5,610 | $0 | $2 |
| Daratumumab injection (Darzalex) | 4,860 | $38 | $189 |
| Darbepoetin injection (Aranesp) for anemia | 4,595 | $2 | $11 |
| Denosumab injection (Prolia/Xgeva) | 2,760 | $18 | $88 |
| Paclitaxel chemotherapy injection | 2,532 | $0 | $2 |
| Injection, paclitaxel protein-bound particles, 1 mg | 2,300 | $10 | $51 |
| Injection, durvalumab, 10 mg | 2,172 | $62 | $296 |
| Dexamethasone injection (steroid) | 1,496 | $0 | $4 |
| Anti-nausea injection (ondansetron/Zofran) | 1,344 | $0 | $5 |
| Immune globulin infusion (Gammagard) | 1,290 | $36 | $137 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,140 | $23 | $184 |
| Injection, bortezomib, 0.1 mg | 560 | $3 | $9 |
| Injection of additional new drug or substance into vein | 354 | $12 | $216 |
| Hospital follow-up visit, low complexity | 338 | $41 | $175 |
| Injection, atropine sulfate, 0.01 mg | 335 | $0 | $2 |
| Anti-nausea injection (Aloxi/palonosetron) | 310 | $1 | $9 |
| Administration of chemotherapy into vein, 1 hour or less | 247 | $97 | $869 |
| Injection, leucovorin calcium, per 50 mg | 220 | $3 | $20 |
| Injection, fluorouracil, 500 mg | 217 | $2 | $28 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 210 | $3 | $34 |
| Office visit, established patient (20-29 min) | 176 | $64 | $296 |
| Injection, carboplatin, 50 mg | 176 | $2 | $31 |
| Collection of blood sample from implanted device | 149 | $18 | $135 |
| Injection, potassium chloride, per 2 meq | 140 | $0 | $22 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 135 | $131 | $500 |
| Drug injection, under skin or into muscle | 113 | $11 | $102 |
| Injection, magnesium sulfate, per 500 mg | 112 | $1 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 97 | $22 | $233 |
| Infusion into a vein for hydration, each additional hour | 94 | $10 | $114 |
| Infusion, normal saline solution , 1000 cc | 81 | $2 | $82 |
| Administration of additional new drug or substance into vein, 1 hour or less | 71 | $50 | $446 |
| Injection, zoledronic acid, 1 mg | 69 | $7 | $55 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 67 | $26 | $200 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 63 | $48 | $426 |
| Administration of chemotherapy into vein, each additional hour | 61 | $22 | $212 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 58 | $55 | $352 |
| Office visit, established patient (30-39 min) | 57 | $102 | $450 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 56 | $16 | $154 |
| Injection, diphenhydramine hcl, up to 50 mg | 42 | $1 | $37 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 33 | $1 | $78 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 32 | $15 | $143 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 27 | $133 | $993 |
| Infusion into a vein for hydration, 31-60 minutes | 23 | $25 | $345 |
| Injection of drug or substance into vein | 20 | $27 | $600 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 19 | $68 | $604 |
| Administration of additional new drug or substance into vein using push technique | 14 | $43 | $370 |
| New patient office visit, complex (60-74 min) | 14 | $177 | $891 |
| Hospital discharge day management, 30 minutes or less | 14 | $65 | $348 |
| New patient office visit (45-59 min) | 11 | $92 | $707 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (76%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Iqbal is a mixed practice specialist, with above-average Medicare volume (top 14% in FL), and consulting-driven industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Iqbal experienced with pembrolizumab injection (keytruda)?
Does Dr. Iqbal receive payments from pharmaceutical companies?
How do Dr. Iqbal's costs compare to other hematology & oncologys in Jacksonville?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology